Skip to main content

BioImage to Use RNAx s RNAi-Knockdown Tool in Its Assay Technology

NEW YORK, Jan. 27 (GenomeWeb News) - RNAx yesterday said it will provide BioImage with its RNAi-knockdown technology.


The agreement will "complement" BioImage's Redistribution assay technology, and "vice versa."


"The goal of the agreement is to provide both RNAx's and BioImage's customers with both technologies from one source, the companies said in s statement.


Financial details of the agreement were not disclosed.

BioImage's Redistribution technology enables high-throughput, high-content screening on many targets of "current interest" in drug discovery, including a "range" of intracellular signaling molecules and cell-surface receptors, the companies said.


RNAx's technology, meantime, provides for automated validation of siRNAs and targets, including those for which BioImage has developed assays.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.